On Wednesday, Shares of Baxalta Inc (NYSE:BXLT), lost -0.74% to $39.10.
Baxalta Incorporated, declared initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)]. ADYNOVATE was approved by the U.S. Food and Drug Administration (FDA) in November 2015 for use in adolescent and adult hemophilia patients (12 years and older) for on-demand treatment and control of bleeding, and prophylaxis to reduce the frequency of bleeding episodes.
The prospective, uncontrolled, open-label, multi-center Phase 3 study was designed to assess the safety and immunogenicity of ADYNOVATE. The study enrolled 73 formerly-treated patients (PTPs) with severe hemophilia A younger than 12 years of age and assessed the treatment’s hemostatic efficacy in prophylaxis and treatment of bleeding episodes. All participants received prophylactic ADYNOVATE treatment (median 1.9 infusions per week) and were followed for six months.
ADYNOVATE met its primary endpoint in the study, as no patients developed inhibitory antibodies to ADYNOVATE. In addition, no treatment-related serious adverse events were stated. More than 70 percent (72.7 percent) of patients had no joint bleeds while on treatment with ADYNOVATE and nearly 40 percent (37.9 percent) practiced zero bleeds. The median annualized bleeding rate (ABR) among patient participants treated with ADYNOVATE was 2.0 (range 0-49.8; mean ABR 3.0), which was comparable to the rates seen in the adult study.
Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets a portfolio of products primarily for the treatment of hematology and immunology worldwide. It also offers other therapies for the treatments of bleeding disorders, and chronic and acute medical conditions, counting hemophilia A, hemophilia B, attained hemophilia, inhibitor treatments, primary immunodeficiency (PID), and alpha-1 antitrypsin deficiency.
Shares of Invesco Ltd. (NYSE:IVZ), declined -0.57% to $33.38, during its last trading session.
Invesco Power Shares Capital Administration LLC, a leading global provider of exchange-traded funds (ETFs) with more than $100 billion in franchise assets, declared changes to its product lineup.
As part of the firm’s commitment to aligning its fund offerings to meet an evolving investment landscape, Invesco Power Shares declared it will change the underlying indexes, but not the index provider for four ETFs. Two of these affected ETFs will also receive new product tickers. There will be no administration fee changes to the affected ETFs.
Four other ETFs are planned to close on Monday, March 21, 2016, with the last day of trading planned for Friday, March 18, 2016. These closures may enable Invesco PowerShares to better align its product line with the changing investment landscape and allow the firm to continue to introduce value-added ETF solutions that meet investor needs going forward.
Invesco Ltd. is a publicly owned investment manager. The firm provides its services to retail clients, institutional clients, high-net worth clients, public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, financial institutions, and sovereign wealth funds. It manages separate client focused equity, balanced, and fixed income portfolios.
Finally, Gold Fields Limited (ADR) (NYSE:GFI), ended its last trade with -1.61% loss, and closed at $2.76.
On Monday, December 28, 2015, Nasdaq Composite ended at 5,040.99, down 0.15%, Dow Jones Industrial Average declined 0.14%, to finish the day at 17,528.27, and the S&P 500 closed at 2,056.5, down 0.22%.
Gold Fields Ltd’s stock reduced by 7.85% to close Monday’s session at USD 2.70. The company’s shares fluctuated in the range of USD 2.68 and USD 2.78. A total of 1.92 million shares exchanged hands, which was lesser than its 50-day daily average volume of 4.84 million shares and its 52-week average volume of 5.23 million shares. Over the last three days Gold Fields Ltd’s shares have declined by 3.57% whereas in the past one week the stock has moved up 1.89%. Furthermore, over the last three months the stock has gained 7.14% while in the past six months the shares have shed 15.8. Gold Fields Ltd has a current dividend yield of 0.66%. Further, the company is trading at a price to earnings ratio of 135.00 and a price to book ratio of 0.75. Additionally, the stock is trading at a price to cash flow ratio of 3.40 and price to sales ratio of 0.87.
Gold Fields Limited operates as a gold mining company. The company engages in the exploration, extraction, processing, and smelting of gold and copper properties. It holds interests in eight operating mines in South Africa, Ghana, Australia, and Peru.
